Abiopharma

New Form DEF 14A - BioSig Technologies, Inc. Filed: 2025-08-04 AccNo: 0001641172-25-022036 Size: 4 MB

New Form 8-K - Iterum Therapeutics plc Filed: 2025-08-04 AccNo: 0000950170-25-101971 Size: 149 KB Item 1.01: Entry into a Material Definitive Agreement

FibroGen to Report Second Quarter 2025 Financial Results

Inspire Medical Systems, Inc. Announces Second Quarter 2025 Financial Results and Updates 2025 Outlook

Quanterix To Report Second Quarter 2025 Financial Results on August 7, 2025

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

New Form 8-K - INTENSITY THERAPEUTICS, INC. Filed: 2025-08-04 AccNo: 0001567264-25-000071 Size: 177 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

Vertex Reports Second Quarter 2025 Financial Results

Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain

Best Brands For Speakers in 2025

New Form 144 - Twist Bioscience Corp Filed: 2025-08-04 AccNo: 0001959173-25-004922 Size: 7 KB

Best Claw Grip Mouse Models for Precision Gaming in 2025